share_log

Citigroup Maintains Sell on PTC Therapeutics, Raises Price Target to $32

Benzinga ·  Dec 4, 2024 11:28  · Ratings

Citigroup analyst David Lebowitz maintains PTC Therapeutics (NASDAQ:PTCT) with a Sell and raises the price target from $26 to $32.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment